A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

NCT05353361 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: SHR-A1811：Pyrotinib
DRUG: SHR-A1811；Pertuzumab
DRUG: SHR-A1811；Adebrelimab
DRUG: SHR-A1811；Albumin paclitaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.